Comparative Pharmacology
Head-to-head clinical analysis: CHLOROFAIR versus HIBISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROFAIR versus HIBISTAT.
CHLOROFAIR vs HIBISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Active against susceptible gram-positive bacteria.
125 mg IV every 6 hours for 10 days.
1.5 mg/kg intravenously every 6 hours; maximum 120 mg per dose.
None Documented
None Documented
4.5 hours (prolonged to 10–12 hours in renal impairment)
Terminal elimination half-life is 2.5–3.5 hours in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Renal: 70% unchanged; hepatic metabolism: 25% conjugated; fecal: 5%
Approximately 90% of absorbed dose excreted renally as unchanged drug; <5% in feces via biliary elimination.
Category C
Category C
Antiseptic
Antiseptic